Non-covalent BTK inhibitor pirtobrutinib shows promise as frontline therapy for CLL/SLL
Non-covalent BTK inhibitor pirtobrutinib shows promise as frontline therapy for CLL/SLL
Linvoseltamab monotherapy in newly diagnosed multiple myeloma shows impressive frontline responses
Pimicotinib in TGCT demonstrates durable responses and sustained functional improvement
Latest in bladder cancer from the second half of 2025
I-DXd shows strong brain metastasis responses in extensive-stage small cell lung cancer with manageable safety
Tarlatamab improves symptoms and QoL over chemo in previously treated SCLC
Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo
Temab-A plus bevacizumab shows promising response rates in advanced colorectal cancer
ESMO 2025: Latest developments in endometrial cancer
ESMO 2025: Precision medicine in bladder cancer
ESMO 2025: Highlights and analysis
PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma